SCHEMBL9016956

SCHEMBL9016956

COC(=O)c1ccc(CNCc2ccc(C(=O)OC)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.68
HPGD P15428 1/20 0.68
LOXL2 Q9Y4K0 1/20 0.66
NPC1 O15118 1/20 0.65
RAB9A P51151 1/20 0.65
CA1 P00915 5/20 0.62
CA2 P00918 5/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
CYP4A11 Q02928 2/20 0.59
CYP4F2 P78329 1/20 0.58
TDP1 Q9NUW8 1/20 0.57
CA12 O43570 1/20 0.57
CA7 P43166 1/20 0.57
CA9 Q16790 1/20 0.57
CA14 Q9ULX7 1/20 0.57
MAPT P10636 2/20 0.57
ALDH1A1 P00352 1/20 0.57
TSHR P16473 1/20 0.54
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15393160 0.98 LMNA (0.66) LMNAHPGDLOXL2NPC1RAB9A
SCHEMBL3746846 0.93 SMN1; SMN2 (0.73) LMNAHPGDLOXL2NPC1RAB9A
SCHEMBL380994 0.93 CA1 (0.73) LMNAHPGDLOXL2NPC1RAB9A
SCHEMBL3310683 0.92 LMNA (0.64) LMNAHPGDLOXL2NPC1RAB9A
SCHEMBL185028 0.91 MEN1 (0.61) LMNAHPGDLOXL2NPC1RAB9A
SCHEMBL1368686 0.91 NPC1 (0.78) LMNAHPGDLOXL2NPC1RAB9A
Hydrochloric Acid SCHEMBL1169317 0.91 SMN1; SMN2 (0.71) LMNAHPGDLOXL2NPC1RAB9A
SCHEMBL7251467 0.91 LOXL2 (0.83) LMNAHPGDLOXL2NPC1RAB9A
SCHEMBL2655924 0.90 HPGD (0.62) LMNAHPGDLOXL2NPC1RAB9A
Hydrochloric Acid SCHEMBL16506822 0.89 CA1 (0.70) LMNAHPGDLOXL2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3328843-B1 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2022-10-26 EP disclosed
CN-109476705-A novel cyclosporin derivatives and use thereof 美国科技环球有限公司 2019-03-15 CN disclosed
US-20180251437-A1 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2018-09-06 US disclosed
EP-3328843-A1 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2018-06-06 EP disclosed
WO-2017018803-A1 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2017-02-02 WO disclosed
WO-2017018803-A1 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2017-02-02 WO disclosed
US-5492954-A STABILIZE LUBRICANTS AND SYNTHETIC POLYMERS AGAINST THE DELETERIOUS EFFECTS OF OXYGEN AND HEAT CIBA-GEIGY CORPORATION (US) 1996-02-20 US disclosed
US-5391808-A Lubricant and synthetic polymer additives for heat and oxidation resistance CIBA-GEIGY CORPORATION (US) 1995-02-21 US disclosed
EP-0585202-A1 N,N'-alkenylene amine/mercaptotolyl-imidazole blends as high temperature antioxidants for elastomers CIBA-GEIGY AG (CH) 1994-03-02 EP disclosed
US-5283367-A Antioxidants for lubricants and polymers CIBA-GEIGY CORPORATION (US) 1994-02-01 US disclosed
US-5240976-A For automobile, wire and cable uses CIBA-GEIGY CORPORATION (US) 1993-08-31 US disclosed
EP-0514333-A2 Substituted 1,4-diamino-2-butene stabilizers and stabilized compositions CIBA-GEIGY AG (CH) 1992-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180251437-A1 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC1, HDAC6, HDAC2 LMNA 3360/4885HPGD 534/4885LOXL2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.